Table 4.
Treatment strategies and efficacy of chloroquine or hydroxychloroquine and combination therapy for COVID-19 in clinical studies.
| Drug | Design | Administration | Dose | Total No. | Effect | References |
|---|---|---|---|---|---|---|
| CQ | RCT | Oral | 500 mg/day (10 days) | 100 | Viral clearance | [10] |
| HCQ | RCT | Oral | 400 mg/day (5 days) | 62 | Recovery time | [113] |
| HCQ | Pilot | Oral | 400 mg/day (5 days) | 30 | Ineffective | [114] |
| HCQ + AZT | SAOLS | Oral | 600 mg/day (10 days) | 42 | Viral load | [10] |
| HCQ + AZT | OS | Oral | 600 mg/day (10 days) | 80 | Viral load | [7] |
| HCQ + AZT | SAOLS | Oral | 600 mg/day (10 days) | 11 | Ineffective | [115] |